Androgen receptor signaling reduces radiosensitivity in bladder cancer

Hiroki Ide, Satoshi Inoue, Taichi Mizushima, Guiyang Jiang, Kuang Hsiang Chuang, Mototsugu Oya, Hiroshi Miyamoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Although radiotherapy often with chemotherapy has been shown to offer a survival benefit comparable with that of radical cystectomy in select patients with bladder cancer, the development of radiosensitization strategies may significantly enhance its application. Notably, emerging preclinical evidence has indicated the involvement of androgen receptor (AR) signaling in urothelial cancer progression. We here assessed whether AR signals could contribute to modulating radiosensitivity in bladder cancer cells. Ionizing radiation reduced the numbers of viable cells or colonies of AR-negative lines more significantly than those of AR-positive lines. Similarly, in AR-positive cells cultured in androgen-depleted conditions, dihydrotestosterone treatment lowered the effects of irradiation. Meanwhile, an antiandrogen hydroxyflutamide enhanced them in AR-positive cells cultured in the presence of androgens. AR knockdown or hydroxyflutamide treatment also resulted in a delay in DNA double-strand break repair 4-24 hours after irradiation. We then established "radiation-resistant" sublines and found considerable elevation of the expression of AR as well as DNA repair genes, such as ATR, CHEK1, and PARP-1, in these sublines, compared with respective controls. Furthermore, dihydrotestosterone induced the expression of these DNA repair genes in irradiated AR-positive cells, and hydroxyflutamide antagonized the androgen effects. Finally, in a mouse xenograft model, low-dose flutamide was found to enhance the inhibitory effects of irradiation, and its tumor size was similar to that of AR knockdown line with radiation alone. These findings suggest that AR activity inversely correlates with radiosensitivity in bladder cancer. Accordingly, antiandrogenic drugs may function as sensitizers of irradiation, especially in patients with AR-positive urothelial cancer.

Original languageEnglish
Pages (from-to)1566-1574
Number of pages9
JournalMolecular Cancer Therapeutics
Volume17
Issue number7
DOIs
Publication statusPublished - 2018 Jul 1

Fingerprint

Radiation Tolerance
Androgen Receptors
Urinary Bladder Neoplasms
Androgens
Dihydrotestosterone
DNA Repair
Cultured Cells
Radiation
Flutamide
Androgen Antagonists
Neoplasms
Double-Stranded DNA Breaks
Cystectomy
Ionizing Radiation
Heterografts
Genes
Radiotherapy
Cell Count

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ide, H., Inoue, S., Mizushima, T., Jiang, G., Chuang, K. H., Oya, M., & Miyamoto, H. (2018). Androgen receptor signaling reduces radiosensitivity in bladder cancer. Molecular Cancer Therapeutics, 17(7), 1566-1574. https://doi.org/10.1158/1535-7163.MCT-17-1061

Androgen receptor signaling reduces radiosensitivity in bladder cancer. / Ide, Hiroki; Inoue, Satoshi; Mizushima, Taichi; Jiang, Guiyang; Chuang, Kuang Hsiang; Oya, Mototsugu; Miyamoto, Hiroshi.

In: Molecular Cancer Therapeutics, Vol. 17, No. 7, 01.07.2018, p. 1566-1574.

Research output: Contribution to journalArticle

Ide, H, Inoue, S, Mizushima, T, Jiang, G, Chuang, KH, Oya, M & Miyamoto, H 2018, 'Androgen receptor signaling reduces radiosensitivity in bladder cancer', Molecular Cancer Therapeutics, vol. 17, no. 7, pp. 1566-1574. https://doi.org/10.1158/1535-7163.MCT-17-1061
Ide, Hiroki ; Inoue, Satoshi ; Mizushima, Taichi ; Jiang, Guiyang ; Chuang, Kuang Hsiang ; Oya, Mototsugu ; Miyamoto, Hiroshi. / Androgen receptor signaling reduces radiosensitivity in bladder cancer. In: Molecular Cancer Therapeutics. 2018 ; Vol. 17, No. 7. pp. 1566-1574.
@article{ff41ac1273f94bf6bbfcca0940f9b3cf,
title = "Androgen receptor signaling reduces radiosensitivity in bladder cancer",
abstract = "Although radiotherapy often with chemotherapy has been shown to offer a survival benefit comparable with that of radical cystectomy in select patients with bladder cancer, the development of radiosensitization strategies may significantly enhance its application. Notably, emerging preclinical evidence has indicated the involvement of androgen receptor (AR) signaling in urothelial cancer progression. We here assessed whether AR signals could contribute to modulating radiosensitivity in bladder cancer cells. Ionizing radiation reduced the numbers of viable cells or colonies of AR-negative lines more significantly than those of AR-positive lines. Similarly, in AR-positive cells cultured in androgen-depleted conditions, dihydrotestosterone treatment lowered the effects of irradiation. Meanwhile, an antiandrogen hydroxyflutamide enhanced them in AR-positive cells cultured in the presence of androgens. AR knockdown or hydroxyflutamide treatment also resulted in a delay in DNA double-strand break repair 4-24 hours after irradiation. We then established {"}radiation-resistant{"} sublines and found considerable elevation of the expression of AR as well as DNA repair genes, such as ATR, CHEK1, and PARP-1, in these sublines, compared with respective controls. Furthermore, dihydrotestosterone induced the expression of these DNA repair genes in irradiated AR-positive cells, and hydroxyflutamide antagonized the androgen effects. Finally, in a mouse xenograft model, low-dose flutamide was found to enhance the inhibitory effects of irradiation, and its tumor size was similar to that of AR knockdown line with radiation alone. These findings suggest that AR activity inversely correlates with radiosensitivity in bladder cancer. Accordingly, antiandrogenic drugs may function as sensitizers of irradiation, especially in patients with AR-positive urothelial cancer.",
author = "Hiroki Ide and Satoshi Inoue and Taichi Mizushima and Guiyang Jiang and Chuang, {Kuang Hsiang} and Mototsugu Oya and Hiroshi Miyamoto",
year = "2018",
month = "7",
day = "1",
doi = "10.1158/1535-7163.MCT-17-1061",
language = "English",
volume = "17",
pages = "1566--1574",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Androgen receptor signaling reduces radiosensitivity in bladder cancer

AU - Ide, Hiroki

AU - Inoue, Satoshi

AU - Mizushima, Taichi

AU - Jiang, Guiyang

AU - Chuang, Kuang Hsiang

AU - Oya, Mototsugu

AU - Miyamoto, Hiroshi

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Although radiotherapy often with chemotherapy has been shown to offer a survival benefit comparable with that of radical cystectomy in select patients with bladder cancer, the development of radiosensitization strategies may significantly enhance its application. Notably, emerging preclinical evidence has indicated the involvement of androgen receptor (AR) signaling in urothelial cancer progression. We here assessed whether AR signals could contribute to modulating radiosensitivity in bladder cancer cells. Ionizing radiation reduced the numbers of viable cells or colonies of AR-negative lines more significantly than those of AR-positive lines. Similarly, in AR-positive cells cultured in androgen-depleted conditions, dihydrotestosterone treatment lowered the effects of irradiation. Meanwhile, an antiandrogen hydroxyflutamide enhanced them in AR-positive cells cultured in the presence of androgens. AR knockdown or hydroxyflutamide treatment also resulted in a delay in DNA double-strand break repair 4-24 hours after irradiation. We then established "radiation-resistant" sublines and found considerable elevation of the expression of AR as well as DNA repair genes, such as ATR, CHEK1, and PARP-1, in these sublines, compared with respective controls. Furthermore, dihydrotestosterone induced the expression of these DNA repair genes in irradiated AR-positive cells, and hydroxyflutamide antagonized the androgen effects. Finally, in a mouse xenograft model, low-dose flutamide was found to enhance the inhibitory effects of irradiation, and its tumor size was similar to that of AR knockdown line with radiation alone. These findings suggest that AR activity inversely correlates with radiosensitivity in bladder cancer. Accordingly, antiandrogenic drugs may function as sensitizers of irradiation, especially in patients with AR-positive urothelial cancer.

AB - Although radiotherapy often with chemotherapy has been shown to offer a survival benefit comparable with that of radical cystectomy in select patients with bladder cancer, the development of radiosensitization strategies may significantly enhance its application. Notably, emerging preclinical evidence has indicated the involvement of androgen receptor (AR) signaling in urothelial cancer progression. We here assessed whether AR signals could contribute to modulating radiosensitivity in bladder cancer cells. Ionizing radiation reduced the numbers of viable cells or colonies of AR-negative lines more significantly than those of AR-positive lines. Similarly, in AR-positive cells cultured in androgen-depleted conditions, dihydrotestosterone treatment lowered the effects of irradiation. Meanwhile, an antiandrogen hydroxyflutamide enhanced them in AR-positive cells cultured in the presence of androgens. AR knockdown or hydroxyflutamide treatment also resulted in a delay in DNA double-strand break repair 4-24 hours after irradiation. We then established "radiation-resistant" sublines and found considerable elevation of the expression of AR as well as DNA repair genes, such as ATR, CHEK1, and PARP-1, in these sublines, compared with respective controls. Furthermore, dihydrotestosterone induced the expression of these DNA repair genes in irradiated AR-positive cells, and hydroxyflutamide antagonized the androgen effects. Finally, in a mouse xenograft model, low-dose flutamide was found to enhance the inhibitory effects of irradiation, and its tumor size was similar to that of AR knockdown line with radiation alone. These findings suggest that AR activity inversely correlates with radiosensitivity in bladder cancer. Accordingly, antiandrogenic drugs may function as sensitizers of irradiation, especially in patients with AR-positive urothelial cancer.

UR - http://www.scopus.com/inward/record.url?scp=85049625843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049625843&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-1061

DO - 10.1158/1535-7163.MCT-17-1061

M3 - Article

VL - 17

SP - 1566

EP - 1574

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 7

ER -